| Autor: |
Costa, Isabela B. S. da S., Bittar, Cristina S., Fonseca, Silvia M. R., e Silva, Carolina M. P. D., dos Santos Rehder, Marilia H. H., Rizk, Stéphanie I., Cruz, Cecilia B. B. V., Figueiredo, Clara S., de A. Andrade, Fernanda T., Barberino, Ludmila de A., de S. Costa, Fernanda A., Machado, Letticya P., González, Thalita B., Almeida, Marcel P. C., Fukushima, Julia T., Kalil Filho, Roberto, Hajjar, Ludhmila Abrahao |
| Předmět: |
|
| Zdroj: |
BMC Cardiovascular Disorders; 4/28/2020, Vol. 20 Issue 1, p1-10, 10p, 3 Diagrams, 3 Charts, 1 Graph |
| Abstrakt: |
Background: In recent years, the field of cardio-oncology has grown worldwide, bringing benefits to cancer patients in terms of survival and quality of life. This study reports the experience of a pioneer cardio-oncology programme at University Cancer Hospital in Brazil over a period of 10 years, describing the clinical profile of patients and the clinical outcomes.Methods: A retrospective study was conducted on a cohort of patients treated at the cardio-oncology programme from April 2009 to February 2019. We analysed the characteristics of patients and outcomes, including mortality, according to the type of clinical indication for outpatient care (general cardiology, perioperative evaluation and follow-up and treatment cardiotoxicity).Results: From a total of 26,435 medical consultations, we obtained the data of 4535 individuals among the medical care outpatients. When we analysed the clinical characteristics of patients considering the clinical indication - general cardiology, perioperative evaluation and cardiotoxicity outpatient clinics, differences were observed with respect to age (59 [48-66], 66 [58-74] and 69 [62-76], p < 0.001), diabetes (67 [15%], 635 [22.6%] and 379 [29.8%]; p < 0.001), hypertension (196 [43.8%], 1649 [58.7%] and 890 [70.1%], p < 0.001) and dyslipidaemia (87 [19.7%), 735 [26.2%] and 459 [36.2%], p < 0.001). A similar overall mortality rate was observed in the groups (47.5% vs. 45.7% vs. 44.9% [p = 0.650]).Conclusion: The number of oncologic patients in the Cardio-Oncology Programme has grown in the last decade. A well-structured cardio-oncology programme is the key to achieving the true essence of this area, namely, ongoing care for cancer patients throughout the disease treatment process, optimizing their cardiovascular status to ensure they can receive the best therapy against cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink